Corvus Pharmaceuticals Announces Publication In Science Signaling Demonstrating ITK Inhibition By Soquelitinib Induces Anti-Inflammatory Treg Cells; Study Highlights Potential For Treating Inflammatory Autoimmune And Allergic Diseases

7/25/24 8:35:13 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CRVS alert in real time by email

Get the next $CRVS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRVS

Date	Price Target	Rating	Analyst
8/18/2023	$7.00	Outperform	Oppenheimer
12/3/2021	$5.00 → $8.00	Overweight	Cantor Fitzgerald
12/1/2021	$8.00	Buy	Jefferies
8/3/2021	$4.00 → $3.50	Neutral	Mizuho
7/16/2021	$9.50 → $6.00	Buy	HC Wainwright & Co.

More analyst ratings

$CRVS
Press Releases

Fastest customizable press release news feed in the world

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and soquelitinib has been granted Orphan Drug Designation and Fast Track Designation by the FDA BURLINGAME, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has initiated a registrational Phase 3 clinical trial of soquelitinib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). The clinical trial is a randomized, controlled study that will evaluate the efficacy and safety of soq
9/10/24 8:30:00 AM ET
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care
Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024. The Company's presentation will be on Tuesday, September 10 at 12:00pm ET. A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relation
9/3/24 4:05:00 PM ET
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of Action Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma (PTCL) Advancing Toward Initial Enrollment in Q3 2024; New Complete Response Achieved in Ongoing Phase 1/1b Clinical Trial Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second
8/6/24 4:01:00 PM ET
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024
BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days. Abou
7/31/24 8:30:00 AM ET
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on May 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days. About Cor
5/2/24 4:02:00 PM ET
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis Orphan drug designation and new interim data from Phase 1/1b clinical trial further demonstrate soquelitinib's potential to address the need for new treatments for PTCL Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023. "Co
3/19/24 4:02:00 PM ET
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care

Corvus Pharmaceuticals Announces Publication In Science Signaling Demonstrating ITK Inhibition By Soquelitinib Induces Anti-Inflammatory Treg Cells; Study Highlights Potential For Treating Inflammatory Autoimmune And Allergic Diseases

Chat with this insight

Recent Analyst Ratings for $CRVS

$CRVS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G filed by Corvus Pharmaceuticals Inc.

$CRVS SEC Filings

Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

SEC Form EFFECT filed by Corvus Pharmaceuticals Inc.

SEC Form S-3 filed by Corvus Pharmaceuticals Inc.

$CRVS Leadership Updates

Live Leadership Updates

$CRVS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

Oppenheimer initiated coverage on Corvus Pharmaceuticals with a new price target

Cantor Fitzgerald reiterated coverage on Corvus Pharmaceuticals with a new price target

Jefferies resumed coverage on Corvus Pharmaceuticals with a new price target

$CRVS Press Releases

Fastest customizable press release news feed in the world

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

$CRVS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Jones William Benton bought $34,624 worth of shares (20,000 units at $1.73), increasing direct ownership by 15% to 153,773 units (SEC Form 4)

Miller Richard A Md bought $1,000,000 worth of shares (577,634 units at $1.73) (SEC Form 4)

$CRVS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Grais Linda

SEC Form 4 filed by Director Clark Ian T

SEC Form 4 filed by Director Morrison Scott W

$CRVS Financials

Live finance-specific insights

$CRVS Market Insights

Live Market Insights

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Corvus Pharmaceuticals Announces Publication In Science Signaling Demonstrating ITK Inhibition By Soquelitinib Induces Anti-Inflammatory Treg Cells; Study Highlights Potential For Treating Inflammatory Autoimmune And Allergic Diseases

Corvus Pharmaceuticals shares are trading lower after the company reported Q1 financial results.

Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $8

Recent Analyst Ratings for
$CRVS

$CRVS
Large Ownership Changes

$CRVS
SEC Filings

$CRVS
Leadership Updates

$CRVS
Analyst Ratings

$CRVS
Press Releases

$CRVS
Insider Purchases

$CRVS
Insider Trading

$CRVS
Financials

$CRVS
Market Insights